Huadong has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream, for the treatment of plaque psoriasis.
A new treatment for erectile dysfunction (ED) has received regulatory approval in the Kingdom of Saudi Arabia, a key ED market, with 10.45% of married males experiencing the condition.
WuXi Biologics expands its biologics conjugation solution center to include space for commercial manufacturing of antibody-drug conjugates for the biopharma industry.
Genentech will collaborate with biopharma company Parvus to manufacture and commercialize Navacim therapeutics for the treatment of autoimmune disease.
Lonza Pharma & Biotech will expand two of its manufacturing sites to reach the capabilities necessary to produce compounds bio-conjugates through to commercialization.
